SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates the launch of the first US Dogecoin ETF, with some speculating on potential price targets. Bullish sentiment is fueled by news of CleanCore planning to buy 1 billion DOGE tokens, indicating confidence in the crypto's future. Social media buzz and increased trading volume suggest growing excitement and potential for further upward movement.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amid a breakout after months of consolidation, with community members actively discussing targets around the $400-$425 range. Some analysts attribute the recent price action to renewed investor confidence or a potential short squeeze, while others suggest the move is detached from fundamentals. Sentiment remains divided, with some highlighting potential resistance levels and others pointing to long-term growth prospects related to AI and robotics.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending with community members pointing to inflows and potential ETF catalysts. Discussions mention institutions increasing their holdings and companies accumulating SOL for their treasuries. Bullish sentiment seems to be growing around Solana's ecosystem and potential for future growth.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Galectin Therapeutics ($GALT) is trending due to a recent surge in price and volume, sparking discussions of a potential short squeeze within the community.  The stock's after-hours activity and significantly above-average volume have captured attention, with some speculating about leaked news or institutional buying.  Community members are referencing positive trial history, key figures connected to the company like Dr. Ben Carson, and a billionaire backer as reasons for their bullish sentiment.

Bonk is the first Solana dog coin for the people, by the people with 50% of the total supply airdropped to the Solana community. The Bonk contributors were tired of toxic “Alameda” tokenomics and wanted to make a fun memecoin where everyone gets a fair shot.

BONK

BONK is trending as the community anticipates a potential burn event upon reaching one million holders and discusses its connection to the Solana ecosystem. Some users are pointing to technical indicators suggesting potential upside, while others highlight its volatility as a meme coin. News of Safety Shot receiving $25 million in BONK coins has also sparked interest.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities is trending as investors anticipate the closing of its merger with Strive, a Bitcoin treasury company, potentially unlocking significant funding. The community is closely watching for news of the merger's completion and speculating about a potential short squeeze, given high short interest and the stock's presence on the Reg SHO list. Discussions also focus on the company's Bitcoin holdings and the possibility of a substantial price increase.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe's earnings are driving significant discussion, with community members debating whether the company's AI initiatives will translate to continued growth or if competition will stifle its performance. Bullish investors are pointing to strong AI adoption and the potential for analyst upgrades, while bears express concern over valuation and decelerating growth. Many are anticipating a volatile after-hours session following the earnings call.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending as the community discusses its correlation to Ethereum's price movements and potential for significant gains. Bullish sentiment is fueled by the company's large ETH holdings and speculation around future staking initiatives. Some traders are also pointing to the company's valuation and the potential for a short squeeze.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid heated debates and politically charged discussions within the community, with users expressing strong opinions and accusations. The conversations touch upon a range of sensitive topics, from political affiliations and ideologies to social issues, with some users pointing fingers and engaging in divisive rhetoric. This increased activity and strong opinions being voiced may be contributing to the stock's current trend.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid takeover speculation, with reports suggesting Paramount Skydance is preparing a bid, potentially backed by Larry Ellison. The community is actively discussing possible buyout prices, some hoping for offers as high as $40 per share, while others temper expectations. The stock's recent surge has ignited discussions around potential short squeezes and the strategic implications for the broader media landscape, including streaming rivals like Netflix.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, PSTX, AE, PFIE on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, PSTX, AE, PFIE on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, PSTX, AE, PFIE on Behalf of...

$TOCKHOLDER ALERT: The MandA Class Action Firm Encourages Shareholders of PFIE, PSTX, ARCH, B to Take Action

$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of PFIE, PSTX, ARCH, B to Take Action $TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of PFIE, PSTX, ARCH, B...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, CCRN, PLL on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, CCRN, PLL on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, CCRN, PLL on Behalf of Shareholders...

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting...

This Week’s Hottest Themes: Biotech (RFK Jr. Meddling), Space (Trump's Space Force),&nbsp; AI (The Theme of the Year)&nbsp;WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in sectors actively drawing capital. This targeted approach, combined with real-time news surveillance, helps us uncover stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.Here's a list of today's most important names:1. Cassava Sciences (NASDAQ: SAVA)Background: Cassava Sciences is a clinical-stage biotechnology company focused on Alzheimer’s disease. Its investigational drug, Simufilam, has been central to its research efforts.The News: Cassava's stock took a dramatic plunge after disappointing Phase 3 trial results for Simufilam, followed by a social media storm triggered by Martin Shkreli’s scathing critique of the drug’s efficacy. Shkreli, calling Simufilam’s mechanism “implausible,” encouraged short-sellers, predicting a sharp decline in the stock. The failure of the trial and Shkreli’s influence sent shares tumbling by more than 85%, from nearly $30 per share to under $5.What It Means: This setback emphasizes the significant risks in Alzheimer's drug development. With most Alzheimer’s trials failing, investors now question the credibility of Cassava’s lead drug. While the company still has resources to pivot, the stock’s credibility has been deeply shaken, and the road ahead is uncertain.Stock Reaction: Yesterday the stock opened at $30 but closed near $5, reflecting a swift and steep sell-off. The market’s reaction shows how quickly investor sentiment can turn negative on biotech stocks, particularly in high-risk, high-reward sectors like Alzheimer’s treatment.&nbsp;2. Poseida Therapeutics (NASDAQ: PSTX)Background: Poseida is a biopharmaceutical company specializing in gene therapies, particularly CAR-T treatments for cancer.The News: Poseida announced a significant partnership with Roche, securing $110 million upfront and up to $1 billion in potential milestones. This deal is aimed at accelerating Poseida's CAR-T therapies and other cell and gene therapy technologies.What It Means: This collaboration is a major validation for Poseida’s technology, especially in the competitive CAR-T space, which has attracted attention due to its potential to treat cancers. The cash infusion from Roche is expected to fuel further research and development.Stock Reaction: Poseida opened at $9.26, up over 200%, rising slightly to close at $9.38. The market responded favorably to the news, viewing the Roche deal as a solid indication of Poseida’s future potential in the cancer treatment landscape.&nbsp;3. KULR Technology Group (NYSE: KULR)Background: KULR specializes in thermal management technologies for energy storage and aerospace.The News: KULR Technology Group has received a U.S. Navy contract to develop its Internal Short Circuit (ISC) technology to operate at higher temperatures. This upgrade is important for both military and commercial applications, especially in aviation where it aligns with safety standards. The ISC devices, originally developed with NASA and NREL, simulate controlled thermal runaway in lithium-ion cells for more accurate and safer testing of battery behavior in extreme conditions.What It Means: The Navy contract could serve as a major stepping stone for KULR, providing the company with exposure to one of the most demanding industries for thermal solutions. This deal not only enhances KULR’s credibility but may also open doors for similar partnerships in the aerospace and defense sectors.Stock Reaction: The stock opened at $0.80 and climbed another 20% reaching $0.96 by mid-morning on volume that is 1,000%+ higher than average.&nbsp;4. POET Technologies (NASDAQ: POET)Background: POET is a leader in photonics technology, designing advanced semiconductor solutions aimed at AI, telecommunications, and data storage.The News: POET Technologies (NASDAQ: POET) is ramping up production of its optical engines to meet the increasing demand from AI applications. A recent report highlighted that while many companies in the UK are adopting AI, few have integrated it into their manufacturing processes, which could hinder innovation and productivity. The report suggests that government support and regulations could help accelerate AI adoption in industries.What It Means: As AI applications continue to expand, POET’s new platform could be a game-changer. The optical interposer aims to address the bottlenecks in data processing by enabling faster, more efficient communication between chips, which is crucial for AI and big data.Stock Reaction: POET opened at $4.38 and rose to $5.35 (up 22%) by mid-day on volume 3x higher than average.&nbsp;5. SurgePays (NASDAQ: SURG)Background: SurgePays provides financial services and prepaid wireless solutions for underserved markets.The News:&nbsp;SurgePays (SURG) has integrated its ClearLine marketing platform with PAX smart payment terminals, allowing merchants to deliver real-time promotions and offers during transactions. This integration leverages existing hardware to enhance customer engagement and streamline marketing efforts, helping retailers boost loyalty and sales. SurgePays aims to scale its retail presence by utilizing PAX's wide reach in the payment terminal industry.What It Means: SurgePays continues to capitalize on the significant need for affordable financial services and wireless solutions in underserved communities. This strong performance suggests the company’s business model is scaling effectively, positioning it well for future growth.Stock Reaction: SurgePays opened at $2.00 and surged to $2.20, up 10%, trading average volume.&nbsp;6. TOYO Ventures Holdings (NASDAQ: TOYO)Background: TOYO Co., Ltd. is a solar solutions company focused on becoming a full-service provider in the global market. It integrates all stages of the solar power supply chain, including wafer and silicon production, solar cell manufacturing, and photovoltaic module production. TOYO is positioned to produce high-quality solar cells at a competitive scale and cost.The News: TOYO Co., Ltd (Nasdaq: TOYO) has secured a $150 million contract to supply high-efficiency solar cells to a major solar module manufacturer. The agreement will support solar module production in India and the U.S., leveraging TOYO’s advanced manufacturing capabilities in Vietnam and Ethiopia. This contract highlights the company's commitment to sustainable energy and the global shift towards renewable resources.What It Means: The $150 million contract is a major win for TOYO Co., Ltd, solidifying its role as a key player in the solar energy sector. It highlights the company’s advanced manufacturing capabilities and global reach, particularly in India and the U.S. For the market, the deal signals continued growth in the solar industry, boosting confidence in renewable energy technologies and potentially attracting more investment. TOYO’s expanded presence in key markets could strengthen its competitive position as demand for efficient solar cells rises..Stock Reaction: Shares opened at $5.56, up 39% to retrace to $4.50 by mid-morning and closing at $5.41 on eye-poping 1,500x average volume.&nbsp;&nbsp;7. Anavex Life Sciences (NASDAQ: AVXL)Background:&nbsp;Anavex Life Sciences develops treatments for neurodegenerative disorders like Alzheimer's and Parkinson's. Its lead drug, ANAVEX®2-73, has shown positive results in Phase 2 trials, while the company is also developing ANAVEX®3-71 for Alzheimer's.The News:Anavex Life Sciences has submitted a Marketing Authorization Application (MAA) for its drug, blarcamesine (ANAVEX®2-73), to the European Medicines Agency (EMA) for the treatment of Alzheimer’s disease. Blarcamesine, an orally administered small molecule, showed significant clinical improvement in patients over 48 weeks, with better efficacy than approved therapies and a slower rate of neurodegeneration in early Alzheimer's patients. Its safety profile eliminates the need for routine MRI monitoring, making it a promising treatment option.What It Means:&nbsp;The MAA submission for blarcamesine to the EMA is a positive development for Anavex Life Sciences, potentially boosting its stock if approved. If successful, blarcamesine could open new revenue streams and strengthen investor confidence. For the broader market, this signals progress in Alzheimer’s treatment, potentially drawing more investment into biotech, especially in neurodegenerative diseases.Stock Reaction: Anavex opened at $10.30 up 10% from Monday's close, but cratered almost 20% from that high by mid-afternoon closing nearly flat from the previous day's close on slightly higher than average volume.&nbsp;&nbsp;Be The First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST&nbsp;SpaceMobile (NASDAQ: ASTS) which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;&nbsp;<hr>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WealthyVC">Follow us on Twitter</a> <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.instagram.com/wealthyventurecapital/">Follow us on Instagram</a> <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/TheWealthyVentureCapitalist/?locale=zh_CN">Follow us on Facebook</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Your Daily Digest of Stocks That Released News Which Moved the Market

Equity

SHAREHOLDER INVESTIGATION: The MandA Class Action Firm Continues to Investigate the Mergers of PSTX, ENLC, BRKH and MNTX

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of PSTX, ENLC, BRKH and MNTX SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate...

POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick and Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Poseida Therapeutics, Inc. (NasdaqGS: PSTX) to...

Shares of Poseida Therapeutics Inc. (<a class="mention" data-mention="$PSTX" data-symbol-id="PSTX" href="https://stocktwits.com/symbol/PSTX" target="_blank">$PSTX</a>) surged over 200% on Tuesday, reaching levels not seen since August 2021, after the company announced its acquisition by Roche Holdings ($RHHBY) in a deal valued at up to $1.5 billion.The stock was the top gainer across U.S. markets early on Tuesday and was among the top 10 trending symbols on Stocktwits.Under the agreement, Poseida stockholders will receive $9.00 per share in cash at closing, along with a non-tradable contingent value right (CVR) of up to $4.00 per share, contingent upon achieving specific milestones.&nbsp;The deal underscores Roche’s interest in Poseida’s proprietary non-viral platform, which enables the development of allogeneic CAR-T therapies enriched with T stem cell memory (TSCM) cells.“Poseida has demonstrated the unique ability of its proprietary non-viral technology platform to create allogeneic, TSCM-rich CAR-T therapies with the potential to improve clinical outcomes and expand access to this important class of medicines,” said Poseida CEO Kristin Yarema.“Most recently, this was highlighted by the compelling interim clinical data for P-BCMA-ALLO1 in patients with multiple myeloma.”Roche’s acquisition also includes Poseida’s cell therapy candidates, manufacturing capabilities, and technology platform.Wall Street analysts reportedly responded with several downgrades for Poseida, citing the definitive valuation set by the acquisition terms.H.C. Wainwright, William Blair, BTIG, and Cantor Fitzgerald all downgraded the stock to ‘Neutral’ or equivalent ratings, noting the fair terms of the $13 per share offer, which includes both upfront cash and milestone-dependent payouts.The acquisition builds on a collaboration between the two companies that began in 2022, focused on CAR-T cell therapies for hematologic malignancies.&nbsp;The merger is expected to close in the first quarter of 2025, with Poseida and its employees set to join Roche’s Pharmaceuticals Division.Retail sentiment on Stocktwits has also turned ‘extremely bullish’, with users highlighting the premium payout as a significant win for shareholders.<stembedurl>https://stocktwits.com/lecorb/message/594107339</stembedurl><stembedurl>https://stocktwits.com/symbol/PSTX</stembedurl>Poseida shares, which had lost over 15% year-to-date before the announcement, are now poised for a dramatic turnaround, driven by investor optimism about the acquisition.&nbsp;For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intc-stock-rises-on-finalizing-chips-act-funding/cJIWnjbRgs">Intel Stock Rises As Chipmaker Secures $7.9B CHIPS Act Funding From Team Biden: Retail Hopes Improve</a>

Roche’s acquisition also includes Poseida’s cell therapy candidates, manufacturing capabilities, and technology platform.

Poseida Therapeutics Stock Hits Over 3-Year Highs On Roche’s $1.5B Buyout Deal: Retail Is Euphoric

The deal underscores Roche's interest in Poseida’s proprietary non-viral platform, which enables the development of allogeneic CAR-T therapies enriched with T stem cell memory cells.

Shareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

Ademi LLP is investigating Poseida (Nasdaq: PSTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Roche. Click here to learn how to join our investigation...

PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Poseida Therapeutics, Inc. (NASDAQ: PSTX) to Roche Holdings, Inc. for $9.00 per share in cash, plus a non-tradeable...

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

Current Price	$9.50
Prev Close	$9.56
Open	$9.58
Dividend Yield	N/A
50-Day Moving Average	$9.50
Beta	0.89
Avg. Volume	0.00
PE Ratio	-15.00

52-Week High	$9.67
52-Week Low	$2.32
Market Capitalization	$925.41M
EPS (Annual)	N/A
Price to Book	10.61
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

PSTX
Poseida Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PSTX News

PSTX Poseida Therapeutics Inc